Related Experiment Video
Updated: Aug 18, 2025
Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
Molecular prognostication in Ph-negative MPNs in 2022
Alessandro Maria Vannucchi1, Paola Guglielmelli1
1CRIMM, Center Research and Innovation of Myeloproliferative Neoplasms, University of Florence, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.
Genomic analysis, including JAK2, MPL, and CALR mutations, improves risk stratification for myeloproliferative neoplasms (MPNs). Novel scores enhance prognostication and stem cell transplant selection, though challenges in predicting leukemia evolution and treatment response remain.
Area of Science:
- Genomics
- Hematology
- Oncology
Background:
- Genomic techniques like cytogenetics and DNA sequencing have transformed myeloproliferative neoplasms (MPNs) diagnosis and management.
- Over 80% of MPN patients harbor driver mutations in JAK2, MPL, or CALR, influencing clinical features, complications, and survival.
- Specific mutations, such as JAK2 V617F and CALR type 1, are integrated into prognostic scoring systems.
Purpose of the Study:
- To discuss the significance and role of genomic analysis in MPN prognostication from a clinical perspective.
- To provide practical guidance on utilizing genomic information for patient management.
- To highlight current unmet needs in MPN molecular prognostication.
Main Methods:
- Review of current literature on genomic techniques in MPN.
- Analysis of the impact of driver mutations (JAK2, MPL, CALR) on clinical outcomes.
- Evaluation of novel integrated clinical and genetic prognostic scores (e.g., MIPSS70/v2, GIPSS, MYSEC-PM).
Main Results:
- Genomic profiling improves risk stratification and aids in predicting thrombosis and survival outcomes in MPNs.
- New integrated scores demonstrate superior performance over conventional scores for prognostication and stem cell transplant candidate selection.
- JAK2 V617F mutation inclusion in risk scores and CALR genotype as a favorable prognostic factor in myelofibrosis (MF).
Conclusions:
- Genomic analysis is crucial for accurate prognostication and personalized management of MPNs.
- Advanced prognostic models incorporating molecular data enhance clinical decision-making, particularly for stem cell transplantation.
- Further research is needed to address challenges in predicting acute leukemia transformation and optimizing targeted therapy selection based on molecular responses.
